MExiletine Versus Lamotrigine in Non-Dystrophic Myotonias (MEND)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05017155 |
|
Recruitment Status :
Recruiting
First Posted : August 23, 2021
Last Update Posted : November 2, 2022
|
| Tracking Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| First Submitted Date ICMJE | August 11, 2021 | ||||||||
| First Posted Date ICMJE | August 23, 2021 | ||||||||
| Last Update Posted Date | November 2, 2022 | ||||||||
| Actual Study Start Date ICMJE | August 12, 2021 | ||||||||
| Estimated Primary Completion Date | August 2023 (Final data collection date for primary outcome measure) | ||||||||
| Current Primary Outcome Measures ICMJE |
Interactive Voice Response (IVR) -diary score [ Time Frame: Time Frame: last two weeks of each treatment period - [Minimum value 0- no myotonia. Maximum value 9 - severe myotonia]. ] Improvement seen on the 9 point Interactive Voice Response (IVR) -diary score
|
||||||||
| Original Primary Outcome Measures ICMJE |
Primary Outcome [ Time Frame: last two weeks of each treatment period - [Minimum value 0- no myotonia. Maximum value 9 - severe myotonia]. ] 9 point Interactive Voice Response (IVR) -diary score
|
||||||||
| Change History | |||||||||
| Current Secondary Outcome Measures ICMJE |
|
||||||||
| Original Secondary Outcome Measures ICMJE |
|
||||||||
| Current Other Pre-specified Outcome Measures | Not Provided | ||||||||
| Original Other Pre-specified Outcome Measures | Not Provided | ||||||||
| Descriptive Information | |||||||||
| Brief Title ICMJE | MExiletine Versus Lamotrigine in Non-Dystrophic Myotonias | ||||||||
| Official Title ICMJE | A Phase III, Randomised, Double Blinded, Head-to-head, Single-site, Cross-over Trial of Lamotrigine Versus Mexiletine for Non-dystrophic Myotonias | ||||||||
| Brief Summary | This is a clinical trial to determine if Lamotrigine is non-inferior to Mexiletine for the treatment of myotonia in patients with Non-Dystrophic Myotonia. Non-dystrophic Myotonia is a genetic condition for which there is no cure. It affects patients for the duration of their life and impacts work, leisure and can lead to significant morbidity. The study is a cross-over design - participants will be randomized to either lamotrigine or mexiletine first for 8 weeks and then swap over after a week wash-out to the other medication for a further 8 weeks. Participants and investigators will be blinded to the treatment schedule. 60 participants will recruited through the clinical service, national registry and national liaison. |
||||||||
| Detailed Description | The current first line treatment for Non-Dystrophic Myotonia (NDM) - Mexiletine - is ineffective in some patients, cannot be used in pregnancy, has side effects and is expensive with limited access in the UK, prompting the clear need for an alternative. A recent open label trial has demonstrated efficacy of Lamotrigine in treating NDMs, raising the possibility of Lamotrigine superseding Mexiletine as the first line agent. As the nationally commissioned highly specialised service for channelopathies, more patients are being seen than in other centres, have a track record of trials in NDMs published in high impact factor journals, and are best placed to conduct a trial of Mexiletine versus Lamotrigine. Clinical morbidity: NDM impairs mobility, causes social embarrassment and impacts on quality of life. NDMs are a group of rare genetic neuromuscular disorders caused by dysfunction of ion channels that are critical for muscle membrane excitability. The hallmark of these disorders is that symptoms occur in an episodic or paroxysmal fashion causing acute disability. The NDMs include myotonia congenita (MC), sodium channel myotonia (SMC) and paramyotonia congenita (PMC). They have a point prevalence in England of 1.12/100,000. MC is due to mutations in the Chloride Channel gene (CLCN1), which codes for the muscle chloride channel clc-1. SMC and PMC are caused by mutations in the Sodium Channel Gene (SCN4A), which codes for the skeletal muscle voltage gated sodium channel Nav1.4. Both of these channels are essential for regulating normal muscle membrane excitability, muscle contraction and relaxation. NDMs are therefore unified by a common pathomechanism of altered muscle membrane excitability. The membrane becomes hyper-excitable resulting in spontaneous depolarisation and contraction after a motor nerve stimulus. The primary clinical manifestation of NDM is myotonia - delayed relaxation of skeletal muscle after contraction. Myotonia is experienced by patients as muscles "locking", "sticking" or "cramping". Symptoms commonly affect the leg muscles and are precipitated by sudden or initial movement leading to falls and injury. They are also exacerbated by prolonged sitting, especially after preceding physical activity, and changes in environmental temperature. This can be particularly problematic on public transport which may stop abruptly, causing falls or inability to exit quickly enough, missing their destination. These difficulties can limit independence, social activity, choice of employment and are often socially embarrassing. The symptomatic relationship with activity often leads to sedentary behaviour which in turn is a risk factor for additional co-morbidities e.g. heart disease or stroke. The condition is frequently painful, with pain and impaired physical ability impacting significantly on quality of life. Symptoms commonly worsen during pregnancy which can be compounded by the need to discontinue current pharmacological therapies due to a lack of safety data during pregnancy. Limitations of current pharmacological therapies: There is currently no cure or disease-modifying treatment for NDM. Sodium channel blockers are used for symptomatic relief. Previously it was shown that Mexiletine is effective in reducing myotonia and improving quality of life in an international randomised placebo controlled trial. Mexiletine has become first line treatment for NDM but not all patients respond to mexiletine and a significant proportion, up to a third develop side effects, the most common being gastro-intestinal. Mexiletine has also been shown to be less beneficial for patients with MC than those with Sodium Channel Myotonia (SCM) or PMC. Additionally, mexiletine cannot be prescribed in pregnancy, when myotonia often worsens. Mexiletine is expensive and can only be accessed by specialist centres. This can have practical difficulties and limit access to treatment for some patients. There is a clear clinical need for an alternative therapeutic option to Mexiletine for the treatment of NDM. The study design has been chosen specifically to allow participants to be internal controls. The degree of myotonia varies with changes in temperature and degree of activity. A highly active participant cannot be directly compared to a sedentary participant, hence the use of internal controls in an 'n of one' trial accounts for this variability. The participants and investigators will be blinded with the use of over-encapsulated mexiletine and lamotrigine dispensed via a predetermined randomisation scheduled. Blinding is important to eliminate bias and in ensuring unbiased completion of subjective questionnaires. |
||||||||
| Study Type ICMJE | Interventional | ||||||||
| Study Phase ICMJE | Phase 3 | ||||||||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Intervention Model Description: Participants will be recruited from University College London Hospital (UCLH). After screening and consent, randomisation will occur to one of two arms. The participant will participate in two consecutive time periods. A time period will consist of 8 weeks of Mexiletine or Lamotrigine. The second time period will then occur after 7 days of washout. The patient will then take the alternative drug. Visits will occur at the end of each period and can be undertaken remotely as required. At each visit, the Interactive Voice Response (IVR)-Diary score will be performed and secondary measures including the Brief Pain Inventory, Modified Fatigue Severity Scale and Medical Outcomes Study Questionnaire (SF-36). Objective recordings including Timed up and Go (TUG), Timed Sit to Stand (TST). Safety data will be recorded simultaneously. A participant diary will be utilised to record daily IVR-Diary scores, medication compliance and activity measures. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment |
||||||||
| Condition ICMJE | Non-Dystrophic Myotonia | ||||||||
| Intervention ICMJE |
|
||||||||
| Study Arms ICMJE |
|
||||||||
| Publications * | Not Provided | ||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
| Recruitment Information | |||||||||
| Recruitment Status ICMJE | Recruiting | ||||||||
| Estimated Enrollment ICMJE |
60 | ||||||||
| Original Estimated Enrollment ICMJE | Same as current | ||||||||
| Estimated Study Completion Date ICMJE | April 2, 2024 | ||||||||
| Estimated Primary Completion Date | August 2023 (Final data collection date for primary outcome measure) | ||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
| Sex/Gender ICMJE |
|
||||||||
| Ages ICMJE | 18 Years to 90 Years (Adult, Older Adult) | ||||||||
| Accepts Healthy Volunteers ICMJE | No | ||||||||
| Contacts ICMJE |
|
||||||||
| Listed Location Countries ICMJE | United Kingdom | ||||||||
| Removed Location Countries | |||||||||
| Administrative Information | |||||||||
| NCT Number ICMJE | NCT05017155 | ||||||||
| Other Study ID Numbers ICMJE | 18/0582 | ||||||||
| Has Data Monitoring Committee | Yes | ||||||||
| U.S. FDA-regulated Product |
|
||||||||
| IPD Sharing Statement ICMJE |
|
||||||||
| Current Responsible Party | University College, London | ||||||||
| Original Responsible Party | Same as current | ||||||||
| Current Study Sponsor ICMJE | University College, London | ||||||||
| Original Study Sponsor ICMJE | Same as current | ||||||||
| Collaborators ICMJE | Not Provided | ||||||||
| Investigators ICMJE | Not Provided | ||||||||
| PRS Account | University College, London | ||||||||
| Verification Date | November 2022 | ||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||